Sign in

You're signed outSign in or to get full access.

BT

Bicara Therapeutics Inc. (BCAX)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 2025 was defined by a major regulatory milestone: FDA granted Breakthrough Therapy Designation (BTD) for ficerafusp alfa plus pembrolizumab in 1L HPV‑negative HNSCC, strengthening the program’s probability of expedited development and regulatory engagement .
  • Operating intensity stepped up with pivotal FORTIFI‑HN01 enrollment and Phase 1b expansion cohorts, driving higher R&D and G&A and a larger net loss; EPS came in at -$0.67, missing Wall Street consensus of -$0.534* as spending ramped to support pipeline execution .
  • Liquidity remains robust: $171.7M cash and cash equivalents plus $236.0M investments at quarter end ($407.6M total), with runway guided “into the first half of 2029,” unchanged versus prior quarters .
  • Near‑term catalysts include additional 1L HPV‑negative HNSCC data at ESMO Asia (750mg weekly cohort) in Q4 2025 and further dose cohort readouts in Q1 2026, supporting dose selection for pivotal FORTIFI‑HN01 .

What Went Well and What Went Wrong

What Went Well

  • FDA granted Breakthrough Therapy Designation for ficerafusp alfa + pembrolizumab in 1L HPV‑negative R/M HNSCC (CPS ≥1), a distinct clinical population with poor outcomes; this validates clinical signals and development strategy .
  • Management emphasized confidence heading into 2026: “Our focus continues to be on executing the enrollment of our pivotal Phase 2/3 FORTIFI‑HN01 trial… We are encouraged by the evolving base of evidence that continues to demonstrate the potential of ficerafusp alfa” .
  • Execution across programs: continued enrollment of FORTIFI‑HN01 and multiple Phase 1b expansion cohorts (HPV‑negative, HPV‑positive heavy smoking history, CRC), indicating broad advancement across indications and dosing strategies .

What Went Wrong

  • Higher operating expenses driven by pivotal trial execution and expansion cohorts increased net loss to $36.3M vs. $17.5M YoY; R&D rose to $33.0M vs. $15.9M and G&A to $7.7M vs. $4.8M YoY, pressuring EPS to -$0.67 .
  • EPS missed consensus (-$0.67 actual vs. -$0.534 estimate*), with the miss attributable to elevated R&D and G&A aligned with trial ramp and personnel costs .
  • Cash and cash equivalents declined to $171.7M from $436.6M in Q2 as capital was reallocated into investments ($236.0M total investments), requiring monitoring of liquidity composition despite runway guidance being maintained .

Financial Results

P&L and Liquidity (quarterly)

MetricQ1 2025Q2 2025Q3 2025
Total Operating Expenses ($USD Millions)$41.788 $32.018 $40.676
Net Loss ($USD Millions)$36.846 $27.388 $36.330
Net Loss per Share ($USD)$0.68 $0.50 $0.67
Interest Income ($USD Millions)$5.014 $4.682 $4.386
Cash & Cash Equivalents ($USD Millions)$462.065 $436.606 $171.673

Operating Expense Detail (quarterly)

MetricQ1 2025Q2 2025Q3 2025
Research & Development ($USD Millions)$34.3 $24.8 $33.0
General & Administrative ($USD Millions)$7.5 $7.2 $7.7

Balance Sheet Investments

MetricQ1 2025Q2 2025Q3 2025
Short‑term Investments ($USD Millions)——$118.494
Long‑term Investments ($USD Millions)——$117.417
Cash, Cash Equivalents & Investments ($USD Millions)n/an/a$407.6

YoY Comparison (Q3)

MetricQ3 2024Q3 2025
Research & Development ($USD Millions)$15.9 $33.0
General & Administrative ($USD Millions)$4.8 $7.7
Net Loss ($USD Millions)$17.5 $36.3
Net Loss per Share ($USD)$1.60 $0.67

KPIs

KPIQ1 2025Q2 2025Q3 2025
Weighted‑avg shares (basic & diluted)54,456,515 54,539,230 54,563,864
Cash runway guidanceH1 2029 H1 2029 H1 2029

Estimates vs. Actual (Q3 2025)

MetricConsensus (Q3 2025)Actual (Q3 2025)Surprise
EPS ($USD)-$0.5338*-$0.67 MISS (-$0.1362)*
Revenue ($USD Millions)$0.0*n/a (pre‑revenue) n/a

Values retrieved from S&P Global.*

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Cash runwayMulti‑yearFund operations into H1 2029 Fund operations into H1 2029 Maintained
750mg weekly cohort (HPV‑neg, 1L HNSCC) data timingQ4 2025Q4 2025 or Q1 2026 ESMO Asia 2025 (Q4 2025) Clarified earlier window
2000mg Q2W cohort (HPV‑neg, 1L HNSCC) data timingQ1 2026Q1 2026 Q1 2026 Maintained
1500mg weekly CPS=0 cohort (HPV‑neg, 1L HNSCC)20262026 2026 Maintained
Phase 1b CRC (mono + pembro; MSS, WT RAS/BRAF)2025–2026Expected to initiate in 2025 Continued to enroll Progressed
Regulatory designation (BTD)Q3 2025None disclosed BTD granted for 1L HPV‑neg HNSCC New positive development

Earnings Call Themes & Trends

TopicQ1 2025Q2 2025Q3 2025Trend
HNSCC pivotal trial enrollment (FORTIFI‑HN01)Enrollment ongoing Enrollment ongoing Continued enrollment Steady execution
Dose regimen exploration (HPV‑neg HNSCC)750mg completed; 2000mg enrolling; CPS=0 enrolling Additional cohorts with data expected Q4’25/Q1’26 ESMO Asia (750mg) Q4’25; more data Q1’26 Increasing clarity on dose
Regulatory milestonesNone highlighted None highlighted FDA BTD granted Positive inflection
Other tumors (CRC)Expected to initiate 2025 Enrolling Continued to enroll Advancement
Cash runwayH1 2029 H1 2029 H1 2029 Maintained
cSCC monotherapy (2L+)ORR 30.4% (7/23), median PFS 7.0m at AACR No updateNo updateNo new readout in Q2/Q3
Corporate——Mgmt team expanded (Cohen, Green, Schelman) Strengthened leadership

Management Commentary

  • “The FDA’s recent Breakthrough Therapy Designation for ficerafusp alfa in first-line HPV-negative HNSCC represents an important milestone… We are encouraged by the evolving base of evidence…” — Claire Mazumdar, CEO .
  • “Updated Phase 1/1b data… underscore the differentiated ability of ficerafusp alfa to remodel the tumor stroma and drive tumor penetration… reinforce our confidence in the [FORTIFI‑HN01] study design.” — Claire Mazumdar, CEO (Q2) .
  • “We continued to execute across our clinical programs… advance FORTIFI‑HN01… updated data… at the 2025 ASCO Annual Meeting… highlighting the broad therapeutic potential of ficerafusp alfa…” — Claire Mazumdar, CEO (Q1) .

Q&A Highlights

  • No Q3 2025 earnings call transcript was found in the document catalog; therefore Q&A details and any call‑specific guidance clarifications are unavailable for synthesis. We searched for an “earnings-call-transcript” between Sep 1 and Nov 20, 2025 and found none for BCAX.

Estimates Context

  • EPS missed consensus: -$0.67 actual vs. -$0.5338 consensus*, reflecting higher R&D and G&A spend associated with pivotal and expansion cohort execution .
  • Revenue is pre‑revenue; consensus was $0.0*, consistent with the company’s development‑stage status (no revenue line in statements of operations) .
  • Near‑term estimate revisions may modestly widen loss expectations given OpEx cadence; however, BTD and upcoming data could improve medium‑term outlook assumptions for pivotal progression and potential regulatory interactions .

Values retrieved from S&P Global.*

Key Takeaways for Investors

  • Regulatory de‑risking: BTD in 1L HPV‑negative HNSCC is a material positive, potentially accelerating FDA interactions and heightening investor confidence in the pivotal path .
  • Execution intensity: Elevated R&D/G&A spending is aligned with pivotal enrollment and multiple expansion cohorts; monitor OpEx trajectory as Phase 2/3 progresses .
  • Liquidity durable: $407.6M total cash, cash equivalents and investments with runway guided into H1 2029 reduces near‑term financing risk amid clinical execution .
  • Data catalysts: ESMO Asia (750mg weekly) in Q4 2025 and Q1 2026 readouts (2000mg Q2W) will inform dose selection and could be stock‑moving events .
  • Broader opportunity: Continued CRC enrollment and prior cSCC monotherapy signal potential beyond HNSCC, supporting platform value across solid tumors .
  • Watch for estimate updates: Post‑BTD and data readouts, sell‑side may adjust timelines and probability of success assumptions; EPS cadence will track OpEx until revenue inflection emerges .
  • Leadership build‑out: Additions to development and corporate affairs strengthen execution capacity entering pivotal years .